CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new preclinical data on ridaforolimus, its investigational mTOR inhibitor being co-developed with Merck, AP24534, its investigational pan-BCR-ABL inhibitor, and AP26113, its investigational anaplastic lymphoma kinase (ALK) inhibitor, have been accepted for seven presentations, including two abstracts in late-breaker sessions, at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., being held April 17 to 21, 2010.
